Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
Background: Programmed death-ligand 1 (PD-L1) may be induced by oncogenic signals or can be upregulated via interferon gamma (IFN-y). We have explored whether the expression of IFNG, the gene encoding IFN-y, is associated with clinical response to the immune checkpoint blockade in non-small cell lun...
| Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | article |
| Publication Date: | 2018 |
| Country: | España |
| Institution: | Universidad de Navarra |
| Repository: | Dadun. Depósito Académico Digital de la Universidad de Navarra |
| Language: | English |
| OAI Identifier: | oai:dadun.unav.edu:10171/65643 |
| Online Access: | https://hdl.handle.net/10171/65643 |
| Access Level: | Open access |
| Keyword: | Immunotherapy Interferon-gamma PD-1 PD-L1 Lung cancer Melanoma |
| Summary: | Background: Programmed death-ligand 1 (PD-L1) may be induced by oncogenic signals or can be upregulated via interferon gamma (IFN-y). We have explored whether the expression of IFNG, the gene encoding IFN-y, is associated with clinical response to the immune checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma patients. The role of inflammation-associated transcription factors STAT3, IKBKE, STAT1 and other associated genes has also been examined. |
|---|